CDKN2A and malignant colon neoplasm: Loss of p16 has been correlated with a strong growth-inhibitory effect in breast and colon cancer cells, whereas high levels of p16 are considered a surrogate marker of Rb loss, and the combination of both has been shown to correlate with ineffectiveness of palbociclib treatment [48, 49].